Opus Genetics, Inc.’s (NASDAQ:IRD) Price Is Right But Growth Is Lacking
Opus Genetics, Inc.’s (NASDAQ:IRD) price-to-sales (or “P/S”) ratio of 4.9x might make it look like a buy right now compared to the Biotechs industry in the United States, where around half of the companies have P/S ratios above 8.7x and even P/S above 59x are quite common. Although, it’s not wise to just take the P/S at face value as there may be an explanation why it’s limited.
Check out our latest analysis for Opus Genetics
